{"analyses":[{"ciLowerLimit":"0.78","ciNumSides":"TWO_SIDED","ciPctValue":"96","ciUpperLimit":"1.24","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.9056","paramType":"Hazard Ratio (HR)","paramValue":"0.99","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14.46","upperLimit":"18.56","value":"16.46"},{"groupId":"OG001","lowerLimit":"12.19","upperLimit":"19.98","value":"15.51"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"432"},{"groupId":"OG001","value":"217"}],"units":"Participants"}],"description":"OS was defined as the time from randomization to death due to any cause.","dispersionType":"96% Confidence Interval","groups":[{"description":"Participants received 40 mg cabozantinib oral tablets once daily + 1200 mg IV infusion of atezolizumab once every 3 weeks for up to 38 months.","id":"OG000","title":"Experimental Arm: Cabozantinib + Atezolizumab"},{"description":"Participants received 400 mg sorafenib oral tablets twice daily for up to 38 months.","id":"OG001","title":"Control Arm: Sorafenib"}],"paramType":"MEAN","populationDescription":"ITT population included all participants randomized to the experimental (cabozantinib + atezolizumab) arm and control (sorafenib) arm.","reportingStatus":"POSTED","timeFrame":"From the date of first participant randomization up to 36 months","title":"Overall Survival (OS) for the Experimental Arm Versus the Control Arm in the ITT Population","type":"PRIMARY","unitOfMeasure":"months"}